Zurcher Kantonalbank Zurich Cantonalbank reduced its position in Novo Nordisk A/S (NYSE:NVO – Free Report) by 77.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,767 shares of the company’s stock after selling 16,200 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Novo Nordisk A/S were worth $243,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Revolve Wealth Partners LLC boosted its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Novo Nordisk A/S by 26.3% during the 2nd quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after purchasing an additional 87,467 shares during the last quarter. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $314,000. Institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Price Performance
Shares of NVO opened at $44.87 on Wednesday. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The company’s fifty day moving average price is $38.45 and its 200-day moving average price is $47.11. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The firm has a market capitalization of $200.34 billion, a PE ratio of 12.93, a price-to-earnings-growth ratio of 10.54 and a beta of 0.77.
Wall Street Analysts Forecast Growth
NVO has been the topic of several research analyst reports. Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Citigroup began coverage on Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating on the stock. Wolfe Research started coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Finally, Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.56.
View Our Latest Analysis on NVO
Key Stories Impacting Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Q1 results beat expectations — adjusted operating profit topped forecasts and the market reacted positively, with coverage noting a share-price jump after the print. Reuters: Novo Nordisk’s first-quarter profit beats forecasts Invezz: Novo Nordisk gains 7% on Q1 beat
- Positive Sentiment: Wegovy pill launch is exceeding expectations — total prescriptions topped ~2 million since launch and early pill sales smashed forecasts, driving the guidance raise. CNBC: Wegovy sales smash forecasts after pill launch as Novo Nordisk hikes guidance WSJ: Wegovy Maker Lifts Guidance; prescriptions data
- Positive Sentiment: Management is pushing to expand the U.S. weight‑loss market and says ~80% of Wegovy users are new patients — a signal the addressable market is growing, not just share-shifting. YouTube: Novo Nordisk CEO: Aim to expand U.S. weight-loss market YouTube Short: Novo CEO: 80% of Wegovy weight-loss users new
- Positive Sentiment: Board-authorized share repurchase program is underway (part of a DKK 15bn programme), which supports per‑share metrics and can stabilize stock in the face of margin volatility. GlobeNewswire: Novo Nordisk share repurchase programme
- Neutral Sentiment: Updated 2026 revenue guidance set at $42.4B–$46.2B (consensus ~$45.4B); the wide range leaves ambiguity around upside vs. expectations and the company’s EPS guidance was not clearly specified in the release.
- Negative Sentiment: Heightened competition and a potential GLP‑1 price war (notably with Eli Lilly) could compress prices and margins; investors will be watching whether rising prescriptions can offset pricing pressure. Reuters: Wegovy pill boom faces price war test Seeking Alpha: Earnings seen as inflection point amid GLP‑1 pricing reset
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Further Reading
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
